نتایج جستجو برای: hemophilia b

تعداد نتایج: 904114  

Journal: :Haematologica 2000
G Tagariello D Belvini R Salviato A Are E De Biasi A Goodeve P Davoli

BACKGROUND AND OBJECTIVE We describe our three year experience in genetic counseling at the Castelfranco Veneto Hemophilia Center, Italy. DESIGN AND METHODS A total of 258 individuals were involved in the study of 142 females. These formed 40 families with hemophilia A and 6 families with hemophilia B. Following pedigree analysis, the FVIII inversion was first examined in severe hemophilia A ...

Journal: :Clinical & Biomedical Research 2023

Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) IX B). Prophylaxis – regular administration therapeutic products to maintain hemostasis and prevent bleeding mainstream treatment. Addressing development scientific evidence for administrating prophylaxis goal this review. modality choice people with sev...

2008
Alexander Edo Tondas

Hemophilia is a hereditaty coagulation disorder which is inherited as an X-link recessive trait. Disorder happens in the intrinsic hemostasis pathway, in which there is a deficiency or defect of coagulation factor VIII (Hemophilia A) or IX (Hemophilia B). Hemophilia is comnron in male, though occurrence in female has also been reported. Female usually are carries. Immunologically, there are sev...

Journal: :Blood 1973
K M Brinkhous P D Davis J B Graham W J Dodds

The linkage distance on the X chromosome between the genes for hemophilia A (classic hemophilia) and B (PTC deficiency, Christmas disease) was estimated directly by breeding two strains of dogs, each segregating for a different type of hemophilia. Gene expression was determined by bioassays of plasma factor VIII (antihemophilic factor) and factor IX (PTC, Christmas factor). Double heterozygotes...

Journal: :Journal of thrombosis and haemostasis : JTH 2011
K Ogata S R Selvaraj H Z Miao S W Pipe

UNLABELLED BACKGROUND & OBJECTIVE  The factor VIII (FVIII) B domain shares very little amino acid homology with other known proteins and is not directly necessary for procoagulant activity. Despite this, missense mutations within the B domain have been reported in patients with hemophilia A. Given that the B domain is dispensable for secretion and function of FVIII, we hypothesized that thes...

Journal: :Blood 2011
Henrik Østergaard Jais R Bjelke Lene Hansen Lars Christian Petersen Anette A Pedersen Torben Elm Flemming Møller Mette B Hermit Pernille K Holm Thomas N Krogh Jørn M Petersen Mirella Ezban Brit B Sørensen Mette D Andersen Henrik Agersø Haleh Ahmadian Kristoffer W Balling Marie Louise S Christiansen Karin Knobe Timothy C Nichols Søren E Bjørn Mikael Tranholm

Current management of hemophilia B entails multiple weekly infusions of factor IX (FIX) to prevent bleeding episodes. In an attempt to make a longer acting recombinant FIX (rFIX), we have explored a new releasable protraction concept using the native N-glycans in the activation peptide as sites for attachment of polyethylene glycol (PEG). Release of the activation peptide by physiologic activat...

Edward Graham Tuddenham, Manijeh Lak, Morteza Karimipour, Nafiseh Nafissi, Peter Green, Sirous Zeinali,

Background: Heterogeneous mutations in the human coagulation factor IX gene lead to an X-linked recessive bleeding disorder known as hemophilia B. The disease is distributed worldwide with no ethnic or geographical priority. Materials and Methods: The aim of this study was to characterize the factor IX gene mutations in 28 unrelated Iranian hemophilia B patients. Polymerase chain reaction (PCR)...

2016
Tuan Huy Nguyen Ignacio Anegon

Hemophilia B is a serious hemostasis disorder due to mutations of the factor IX gene in the X chromosome. Gene therapy has gained momentum in recent years as a therapeutic option for hemophilia B. In hemophilia, reconstitution with a mere 1–2% of the clotting factor improves the quality of life, while 5–20% suffices to ameliorate the bleeding disorder. A paper by Guan et al (2016) in this issue...

Journal: :Hematology. American Society of Hematology. Education Program 2010
Claire Philipp

Improvements in hemophilia care and antiviral treatments have resulted in increases in median life expectancy for persons with congenital hemophilia A and B. Currently, 2% of hemophilia A and B patients surveyed in US comprehensive hemophilia treatment centers are 65 years of age or older and 15% are 45 years or older. Many of the complications of hemophilia, including intracranial hemorrhage, ...

Journal: :Blood 2005
Paula D James Sanj Raut Georges E Rivard Man-Chiu Poon Margaret Warner Susan McKenna Jayne Leggo David Lillicrap

Aminoglycoside antibiotics exhibit their bactericidal effect by interfering with normal ribosomal activity. In this pilot study, we have evaluated the effect of the aminoglycoside antibiotic gentamicin on the factor VIII (FVIII) and IX levels of severe hemophiliacs with known nonsense mutations. Five patients were enrolled and each patient was given 3 consecutive days of gentamicin at a dose of...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید